A streamlined, high-throughput platform for validation of cancer antigen presentation and isolation of cancer antigen reactive T cells

一个简化的高通量平台,用于验证癌症抗原呈递和分离癌症抗原反应性 T 细胞

基本信息

  • 批准号:
    10272349
  • 负责人:
  • 金额:
    $ 39.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-23 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Abstract T cell receptor (TCR) based cancer immunotherapies, either infusing expanded patient autologous tumor- specific T cells or infusing cancer-specific TCR engineered autologous T cells, have shown great clinical benefit in several types of cancer. However, two challenges have prevented the broad application of these therapies to many types of cancer. First, there lacks a quick and sensitive method to detect patient-specific presentation of cancer antigen peptides on the surface of tumor cells. Second, there lacks a rapid method for the isolation of antigen-specific T cells that can be propagated quickly in vitro to meet the real-time needs of adoptive cell transfer therapy. These challenges have become road blocks for the application of TCR based cancer immunotherapy to many types of cancer and have prevented the exploration of other classes of cancer-antigens in addition to neo-antigens (NeoAs) that also have therapeutic potential, such as cancer germline antigens (CGA). In this study, we propose the development of AbTR (Antigen sensing-based T cell Recall) technology to address these two critical challenges in large scale. The AbTR technology will provide a quick and streamlined path to identify cancer antigens presented on tumor cell from hundreds of possible targets and isolate many antigen- specific T cell clones that are functionally capable of killing tumor cells and are ready to be used in adoptive cell transfer therapy. The success of the project address two urgent needs in cancer immunotherapy. This technology not only can be applied to all types of cancer but may also be relevant for the study of other immunological diseases, such as infection and autoimmune diseases.
摘要 基于T细胞受体(TCR)的癌症免疫疗法,或者输注扩增的患者自体肿瘤- 特异性T细胞或输注癌症特异性TCR工程化自体T细胞,已经显示出巨大的临床益处 在几种癌症中。然而,两个挑战阻碍了这些疗法的广泛应用, 多种癌症。首先,缺乏一种快速和敏感的方法来检测患者特异性的 肿瘤细胞表面的癌抗原肽。第二,缺乏快速的分离方法, 抗原特异性T细胞,可在体外快速增殖,以满足过继细胞转移的实时需求 疗法这些挑战已经成为基于TCR的癌症免疫治疗应用的障碍 许多类型的癌症,并阻止了探索其他类别的癌症抗原,除了 也具有治疗潜力的新抗原(NeoA),如癌生殖系抗原(CGA)。 在这项研究中,我们提出了AbTR(抗原传感为基础的T细胞召回)技术的发展,以解决 这两个关键的挑战。AbTR技术将提供一个快速和简化的路径, 从数百种可能靶点中鉴定肿瘤细胞上呈递的癌抗原,并分离出许多抗原- 特异性T细胞克隆,其在功能上能够杀死肿瘤细胞,并准备用于过继细胞 转移疗法该项目的成功解决了癌症免疫治疗的两个迫切需求。这项技术 不仅可以应用于所有类型的癌症,而且还可能与其他免疫学研究有关。 疾病,如感染和自身免疫性疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Amy Brock其他文献

Amy Brock的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Amy Brock', 18)}}的其他基金

Instability of Cancer Cell States in Tumor progression (ICCS)
肿瘤进展过程中癌细胞状态的不稳定性 (ICCS)
  • 批准号:
    10491691
  • 财政年份:
    2021
  • 资助金额:
    $ 39.49万
  • 项目类别:
A streamlined, high-throughput platform for validation of cancer antigen presentation and isolation of cancer antigen reactive T cells
一个简化的高通量平台,用于验证癌症抗原呈递和分离癌症抗原反应性 T 细胞
  • 批准号:
    10493222
  • 财政年份:
    2021
  • 资助金额:
    $ 39.49万
  • 项目类别:
Instability of Cancer Cell States in Tumor progression (ICCS)
肿瘤进展过程中癌细胞状态的不稳定性 (ICCS)
  • 批准号:
    10212099
  • 财政年份:
    2021
  • 资助金额:
    $ 39.49万
  • 项目类别:
Systems Approaches to Understanding Subpopulation Heterogeneity in Therapeutic Resistance
理解治疗耐药性亚群异质性的系统方法
  • 批准号:
    10057183
  • 财政年份:
    2020
  • 资助金额:
    $ 39.49万
  • 项目类别:
Systems Approaches to Understanding Subpopulation Heterogeneity in Therapeutic Resistance
理解治疗耐药性亚群异质性的系统方法
  • 批准号:
    10256717
  • 财政年份:
    2020
  • 资助金额:
    $ 39.49万
  • 项目类别:
Systems Approaches to Understanding Subpopulation Heterogeneity in Therapeutic Resistance
理解治疗耐药性亚群异质性的系统方法
  • 批准号:
    10468211
  • 财政年份:
    2020
  • 资助金额:
    $ 39.49万
  • 项目类别:
Systems Approaches to Understanding Subpopulation Heterogeneity in Therapeutic Resistance
理解治疗耐药性亚群异质性的系统方法
  • 批准号:
    10524210
  • 财政年份:
    2020
  • 资助金额:
    $ 39.49万
  • 项目类别:
Systems Approaches to Understanding Subpopulation Heterogeneity in Therapeutic Resistance
理解治疗耐药性亚群异质性的系统方法
  • 批准号:
    10307901
  • 财政年份:
    2020
  • 资助金额:
    $ 39.49万
  • 项目类别:
Systems Approaches to Understanding Subpopulation Heterogeneity in Therapeutic Resistance
理解治疗耐药性亚群异质性的系统方法
  • 批准号:
    10388446
  • 财政年份:
    2020
  • 资助金额:
    $ 39.49万
  • 项目类别:
Systems Approaches to Understanding Subpopulation Heterogeneity in Therapeutic Resistance
理解治疗耐药性亚群异质性的系统方法
  • 批准号:
    10759093
  • 财政年份:
    2020
  • 资助金额:
    $ 39.49万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 39.49万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 39.49万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.49万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.49万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 39.49万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.49万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 39.49万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 39.49万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 39.49万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.49万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了